Session » (0582–0608) SLE – Treatment Poster I

Date: Sunday, November 12, 2023

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2023

9:00AM-11:00AM: Abstract Number: 0589

A Comparative Evaluation of IgA2 Anti-dsDNA Antibodies and Clinical Outcome in Two Clinical Trials of Belimumab After Rituximab in SLE

9:00AM-11:00AM: Abstract Number: 0603

Antiphospholipid Antibodies as Potential Predictors of Disease Severity and Poor Prognosis in Systemic Lupus Erythematosus Associated Thrombocytopeinia

9:00AM-11:00AM: Abstract Number: 0594

Baseline Innate Immunity Transcriptional Signatures Act as Predictors of Response to Immunosuppressive and Biologic Treatments in Systemic Lupus Erythematosus While Disturbances Linked to p53-signaling Define “Resistant” Disease

9:00AM-11:00AM: Abstract Number: 0607

CAR T Cell Therapy Leads to Long-term Abrogation of Autoimmunity in SLE Patients While Vaccination Responses Are Maintained

9:00AM-11:00AM: Abstract Number: 0590

Comparing Safety and Efficacy of Sodium-Glucose Co-Transporter 2 Inhibitors versus Dipeptidyl Peptidase 4 Inhibitors in Patients with Systemic Lupus Erythematosus and Comorbid Type 2 Diabetes Mellitus

9:00AM-11:00AM: Abstract Number: 0591

Despite Dramatic Expansion of Approved Biologics in SLE, Unmet Needs Remain

9:00AM-11:00AM: Abstract Number: 0605

Determining the ECG Cut-off Point in Systemic Lupus Erythematosus Patients Undergoing Hydroxychloroquine Therapy

9:00AM-11:00AM: Abstract Number: 0596

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial in Systemic Lupus Erythematosus (SLE): Achievement of Sustained SRI(4), BICLA and Dual Responses over 48 Weeks

9:00AM-11:00AM: Abstract Number: 0602

Dual Blockade of ICOS and CD28 with Acazicolcept (ALPN-101) Reveals Non-Redundant Roles of T Cell Co-Stimulation Pathways in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0597

Efficacy of Anifrolumab in Systemic Lupus Erythematosus by Overall and Organ-Specific SLEDAI-2K Improvements: Results from the Randomized, Placebo-Controlled Phase 3 Long-Term Extension Study

9:00AM-11:00AM: Abstract Number: 0608

Efficacy of Cenerimod in Patients with High IFN-1 Gene Expression Signature and High Anti-dsDNA Antibody Levels: Post-hoc Analysis from a Phase 2 Study

9:00AM-11:00AM: Abstract Number: 0582

Evaluation of Anifrolumab Treatment Responses by the Short Form 36 Health Survey Version 2 in SLE: A Post Hoc Analysis of the Placebo-Controlled Phase 3 Long-Term Extension Trial

9:00AM-11:00AM: Abstract Number: 0600

Identification of Subsets of SLE Patients Responsive to Baricitinib by Transcriptomic Analysis at Baseline

9:00AM-11:00AM: Abstract Number: 0587

Impact of up to 24 Months Intravenous (IV) Belimumab (BEL) Treatment on Steroid Use and Disease Activity in Patients with SLE in Clinical Practice: Additional Post Hoc Pooled Analysis of Multicountry OBSErve Cohort Data

9:00AM-11:00AM: Abstract Number: 0604

Is Belimumab Dose Optimization Possible in Patients with Systemic Lupus Erythematosus?: Analysis of This Therapeutic Strategy in a Large Multicenter Cohort of Patients from Spanish Rheumatology Departments

9:00AM-11:00AM: Abstract Number: 0598

Litifilimab Modulates Type I IFN Biomarkers in Patients with SLE or CLE in the Phase 2 LILAC Study

9:00AM-11:00AM: Abstract Number: 0588

Long Term Safety and Predictors of Serious Infections Among Patients with Systemic Lupus Erythematosus Treated with Rituximab: Audit from a Single Center Biologic Registry

9:00AM-11:00AM: Abstract Number: 0593

Lupus Nephritis of the Spanish National Registry of Belimumab in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0592

Real-World Treatment Patterns in Patients with Systemic Lupus Erythematosus: An Analysis of the SLE Prospective Observational Cohort Study (SPOCS)

9:00AM-11:00AM: Abstract Number: 0595

Renal Involvement in Patients with Systemic Lupus Erythematosus Treated with Anifrolumab Compared with Placebo over a 4-Year Period

9:00AM-11:00AM: Abstract Number: 0606

Risk of Damage Progression with Belimumab versus Oral Immunosuppressant Use in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0601

Selective Disposition of Voclosporin, Cyclosporine, and Tacrolimus in Renal Tissue

9:00AM-11:00AM: Abstract Number: 0599

Targeted Inhibition of Cathepsins Limits the Intracellular Complement Activation in Lupus Nephritis Podocytes

9:00AM-11:00AM: Abstract Number: 0584

Targeting Key Components of SLE Pathogenesis with the Multifaceted Immunomodulatory Properties of Cenerimod, a Selective S1P1 Receptor Modulator

9:00AM-11:00AM: Abstract Number: 0585

The Impact of Impaired Vagus Nerve Activity and Transcutaneous Vagus Nerve Stimulation (tVNS) on Arterial Stiffness in Systemic Lupus Erythematosus (SLE)

9:00AM-11:00AM: Abstract Number: 0586

Therapeutic Drug Monitoring of Azathioprine and Tacrolimus in SLE Pregnancies: Preliminary Results from the LEGACY Cohort

9:00AM-11:00AM: Abstract Number: 0583

Therapeutic Potential of Imvotamab, a CD20-Targeted Bispecific IgM T Cell Engager, for the Treatment of Refractory Autoimmune Disease Patients

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].